MedTrace Logo

Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT

NCT02702505 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-03-08

No results posted yet for this study

Summary

Mineral trioxide aggregate has been previously FDA approved as an endodontic filler. Its use in vital teeth has demonstrated significant color change post-treatment leaving it ineffective for esthetic use..

The new formulation will be tested to see if has the same effect.

Conditions

  • Reversible Pulpitis
  • Dental Pulp Diseases

Interventions

BIOLOGICAL

NeoMTA

A new formulation of MTA was developed in which bismuth oxide was omitted

OTHER

ProRoot MTA

Control group

Sponsors & Collaborators

  • Texas A & M University Baylor College Of Dentistry

    lead OTHER

Principal Investigators

  • Carolyn A Kerins, DDS, PhD · Texas A & M University Baylor College Of Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702505 on ClinicalTrials.gov